Sartorius sees solid growth in fiscal year, expects strong growth in 2023

Sartorius AG, a leading international partner of the biopharmaceutical industry, reported solid growth in the 2022 fiscal year despite a challenging market environment.

For the full year, Sartorius increased sales by 17.5% to 4.22 billion euros, driven by strong growth in both the Bioprocess Solutions and Lab Products & Services divisions.

The company also saw a significant increase in its order intake, which rose by 26.4% to 4.84 billion euros, indicating continued strong demand for its products and services from the biopharmaceutical industry.

In terms of profitability, Sartorius reported an adjusted EBITDA margin of 30.7%, compared to 30.2% in the previous year. The company attributed this improvement to its strong sales growth and efficient cost management.

Looking ahead to 2023, Sartorius expects to continue to grow strongly, with sales expected to increase by between 15% and 19% and adjusted EBITDA margin expected to be in the range of 29.5% to 30.5%.

The company cited several factors driving its positive outlook, including the continued strong demand for its products and services from the biopharmaceutical industry, its ongoing investments in innovation, and its focus on operational excellence.

Sartorius is well-positioned to continue to benefit from the growing demand for biopharmaceuticals, which are used to treat a wide range of diseases, including cancer, diabetes, and autoimmune disorders.

The company is also investing heavily in innovation, with a focus on developing new products and technologies that can help its customers bring new therapies to market faster and more efficiently.

In addition, Sartorius is focused on operational excellence, and is working to improve its efficiency and productivity, which will help to drive profitability and support continued growth.

Overall, Sartorius is well-positioned to continue to grow strongly in the years to come, and is a company that investors should keep an eye on.